StockData
ACRVNasdaqPharmaceutical PreparationsFiscal year ends December 31

Acrivon Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.69+0.05 (+3.05%)

Close on Oct 19, 2026

Market cap
$70.71M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 12, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 12, 2026After market close–$-0.43–
Q1 FY2026
Ended Mar 31, 2026
May 13, 2026After market close–$-0.49–
Q4 FY2025
Ended Dec 31, 2025
Mar 19, 2026Before market open–$-0.49–
Q3 FY2025
Ended Sep 30, 2025
Nov 13, 2025After market close–––
Q2 FY2025
Ended Jun 30, 2025
Aug 13, 2025After market close–$-0.55–
Q1 FY2025
Ended Mar 31, 2025
May 14, 2025After market close–$-0.51–
Q4 FY2024
Ended Dec 31, 2024
Mar 25, 2025After market close–––
Q3 FY2024
Ended Sep 30, 2024
Nov 13, 2024Before market open–$-0.59–
Q2 FY2024
Ended Jun 30, 2024
Aug 13, 2024Before market open–$-0.52–
Q1 FY2024
Ended Mar 31, 2024
May 14, 2024Before market open–$-0.73–
Q4 FY2023
Ended Dec 31, 2023
Mar 28, 2024Before market open–$-0.86–

Press releases

Announcements Acrivon Therapeutics filed with the SEC